Home      Tickers | SPY | NQ100 | DOW | Global | ETFs | Sector ETFs | 3x ETFs | ETF Movers | Stock Movers | Trading Alerts
     ^  TNXP:  Intraday  Hourly  Forecast  Similar  Waves  GapOpen  Research  Timing  Gains  Losses  Strategies  Practice
     Tue. Oct. 20, 2020

Trading Signals: TNXP Stock Price Prediction and Forecast (Fri. Feb. 3, 2012 - Fri. May. 13, 2022)

(Tonix Pharmaceuticals)

Market is closed on Tue. Oct. 20, 2020


Trend Analysis and Forecast
 
Average Daily Percentage Swing  0% (three month average)
RSI   
Latest Price   $(0%)
Stocks Behave Similarly  Similar Stock List
Market Behavior  Value stock rally for large cap. Value stock rally for small cap.
Correlated ETFs  Broad market will support TNXP advance at 0% a week (0% probability)
  XHB(15%)    BWX(11%)    XRT(10%)    IBB(9%)    EWY(8%)  
Factors Impacting TNXP price  TNXP will advance at least -0% in a week (0% probabilities).
  VCSH(-15%)    BNDX(-14%)    VIXM(-12%)    JETS(-11%)    UUP(-10%)  
 
 
Relative Volatility  
 
Market Trend Strength  0% (StdDev 0%)
Hourly BBV   0.9 ()
Intraday Trend   NAN%
  
 

  

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecules and biologics to treat psychiatric, pain and addiction conditions, to improve biodefense through potential medical counter-measures, to treat transplant rejection and to treat gastric and pancreatic cancers. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and Tonmya. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in New York, NY.

July 16, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it has entered into a research collaboration and option agreement with Columbia University focused on studying the immune responses to COVID-19 in healthy volunteers who have recovered from COVID-19 or were asymptomatic. The research collaboration will focus on T cell and antibody responses to SARS-CoV-2 (CoV-2), the virus that causes COVID-19 at the cellular level including human monoclonal antibodies and anti-idiotypes. The research is designed to fill in important gaps in understanding the detailed immune responses to COVID-19, and to provide a foundation upon which to target vaccines and therapeutics to appropriate individuals by precision medicine.

$. TNXP price fluctuates within NAN% (three month std-dev: 0%) daily (68% of days).

getNextHourMoveProbability failed